The more assumptions you have to make, the more unlikely an explanation is.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CFRX- ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018
YONKERS, N.Y., May 30, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of new data on its lead drug candidate, CF-301 (exebacase), and its Gram-negative lysin discovery program at American Society for Microbiology (ASM) Microbe 2018, to be held from June 7-11, 2018, in Atlanta.
The presentations include results from new in vivo, in vitro, and surveillance studies of ContraFect’s lead lysin CF-301 (exebacase), which is currently being studied in a Phase 2 clinical trial for the treatment of Staphylococcus aureus (Staph aureus) bacteremia, including endocarditis. Data will be presented which demonstrates CF-301’s activity against a broad range of Staphylococcus and Streptococcus bacteria known to cause bacteremia and endocarditis, activity against contemporary clinical isolates of Staph aureus from U.S. hospitals, and ability to suppress emergence of vancomycin resistance. For the first time, data on CF-301’s novel ability to synergize with and activate host factors in human serum will be presented. ContraFect will also present initial in vitro proof of principle data from the Gram-negative lysin discovery program demonstrating the bactericidal effect of its newly discovered lysins against multi-drug resistant (MDR) Pseudomonas aeruginosa.
“We are pleased to return to ASM this year and present important new data which expands our understanding of CF-301’s spectrum of action of against a broad range of Staph and Strep species and provides new insight into the compound’s novel ability to activate latent host factors in human blood which enhance bactericidal activity,” said Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development at ContraFect. “We are also excited to unveil the first data on the bactericidal and anti-biofilm activity of Gram-negative lysins discovered in our laboratory against MDR Pseudomonas aeruginosa. We look forward to continuing to present new data from our active lysin research programs as we await top-line results from the ongoing Phase 2 trial of CF-301 later this year,” continued Dr. Cassino.
Presentation Details:
Presentation Title: Bacteriophage Lysins Can Be Engineered to Exert a Rapid and Potent Bactericidal Effect against Pseudomonas aeruginosa in Serum
Session Day & Time: Sunday, June 10, 2018, 12:45 p.m. – 2:45 p.m. ET
Poster Board Number: SUNDAY - HMB LB14
Session Title: Session 384 - SUNDAY - HMB Late-breakers
Presentation Title: Lysin CF-301 Demonstrates Potent in Vitro Activity against a Range of Staphylococcus and Streptococcus Species Associated with Complicated Bacteremia and Infective Endocarditis in Humans
Session Day & Time: Sunday, June 10, 2018, 12:45 p.m. – 2:45 p.m. ET
Poster Board Number: SUNDAY - AAR LB5
Session Title: Session 403 - SUNDAY - AAR Late-breakers
Presentation Title: CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals
Session Day & Time: Sunday, June 10, 2018, 12:45 p.m. – 2:45 p.m. ET
Poster Board Number: SUNDAY - 530
Session Title: Session 410 - AAR08 - New Antimicrobial Agents and New Research Technologies: Bacteriophage-Related Tools and Therapy
Presentation Title: Lysin CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the Emergence of Reduced Susceptibilities to VAN Within Cardiac Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)
Session Day & Time: Sunday, June 10, 2018, 12:45 p.m. – 2:45 p.m. ET
Poster Board Number: SUNDAY - 535
Session Title: Session 410 - AAR08 - New Antimicrobial Agents and New Research Technologies: Bacteriophage-Related Tools and Therapy
Presentation Title: Lysin CF-301 Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis
Session Day & Time: Sunday, June 10, 2018, 12:45 p.m. – 2:45 p.m. ET
Poster Board Number: SUNDAY - 536
Session Title: Session 410 - AAR08 - New Antimicrobial Agents and New Research Technologies: Bacteriophage-Related Tools and Therapy
The abstracts can be accessed through the ASM Microbe website. Following the meeting, the presentation posters will be available on the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza. ContraFect’s lead product candidate, CF-301, is currently in a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S. ContraFect is also conducting research focused on the discovery of lysins to target Gram-negative bacteria.
About CF-301 (exebacase):
CF-301 (exebacase) is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect. It is the first lysin to enter clinical studies in the U.S.
Infinity bottom...
TRVN moving through resistance points. Sept'ish adcom Nov pdufa.
TRVN moving through resistance points. Sept'ish adcom Nov pdufa.
RJD Green Inc. Announces the Initial Contract of the WellBen Joint Venture for $240,000Press Release | 05/30/2018
TULSA, OK, May 30, 2018 (GLOBE NEWSWIRE) -- RJD Green (OTCPK: RJDG), announced the WellBen joint venture received its initial contract of $240,000 in annual services. The joint venture launched in March is focused in delivery of health and wellness benefit programs.
RJD Green Inc. announced the initial contact of their joint venture with WellBen Group, a certified counselors group, offering health and wellness programs. WellBen, as a service organization, creates customized wellness programs that are designed to uniquely achieve best outcomes for both the employee and employer while meeting all the employer’s needs and expectations.
RJD Green and WellBen are launching the mutual marketing of products and services offered by the combined companies.
Initial RJD Green offerings are the products and services of IoSoft Inc. IoSoft offers innovative and proprietary payment processing platforms for firms with 100 employees to 1,00,000 employees.
Ron Brewer, CEO of RJD Green Inc. states, “We feel the WellBen Group is doing an excellent job of launching their comprehensive regional to national marketing and business development program. They are bringing forward multiple business opportunities to explore as the joint venture is launched.”
Jeff Bebee, WellBen Group President stated, "We are pleased with our reception and interest from municipalities and business corporations in launching. We are also creating market awareness of RJD Green’s IoSoft payment platform of services for businesses in multiple sectors.”
Both IoSoft Inc. and WellBen Group offer a platform of services and products that are unique to their fields of endeavor, yet are soliciting client contacts with common needs of both company’s offerings.
WellBen’s market focus is municipalities and government agencies, along with business owners with 100 employees to corporations with 1,000,000 employees. This gives IoSoft potential market penetration in markets we have not entered yet. The same principle applies for WellBen as they have no marketing presence in health services, which is IoSoft’s focus in launching its unique payment processing platforms.
DOVA-Tute holding up 3.66% last 7 days 94% Institutional Shares 24,280,958 - 94.55% (ex. N-Q) This boggles my mind.
Nice!
$1.80 held for now, yay! Anybody read/write Korean? lol
Hahaha...Noooo. It moved due to rule 201.
DOVA--current/yesterday presentation great analysts Q&A http://investors.dova.com/events/event-details/dova-pharmaceuticals-investor-update
DOVA- will require patience, but they have all the components of a growth bio. (for now)
Since I brought it up fyi- EBIO from what I can tell the update due 6/21 will take place Monday, 5/21.
Good year so far, decided to concentrate hahaha.
EBIO up 26%
Oops DOVA
DOVE- Tutes up to 90.86% https://fintel.io/so/us/dova
FYI-New (FDA) arthritis medication, joint injection: http://www.koreabiomed.com/news/articleView.html?idxno=3219
Great Q1 numbers after a year of "audit wringer".
Gross revs continue to grow, net revenues positive. Excellent news.
DOVA up 6.42%.
PLUG--maybe some those massive shorts got too greedy
Somebody got a nice discount at .0091
Looks like shorts maybe got too greedy.
Nice! Glty :)
CFRX -- their P2 trial represents one of the new faces in the infectious disease battle. I bought a reasonable amount yesterday, early on purpose.
CF-301 has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia. https://www.contrafect.com/pipeline/overview
Lysins are enzymes that digest the bacterial cell wall and kill bacteria rapidly upon contact, much faster than conventional antibiotics which typically require time for bacterial metabolism to occur before killing bacteria or stopping their growth. Other features which differentiate our lysins from standard antibiotics include antimicrobial activity against antibiotic-resistant bacteria, specificity for target bacteria while preserving the healthy microbiome, and the ability to clear biofilms which can shield bacteria from destruction. In addition, lysins act synergistically with standard of care antibiotics and can reduce the development of resistance to these antibiotics when administered concomitantly. Lysins themselves have very low propensity for resistance.
https://www.contrafect.com/technology/overview
Hear! Hear!
DOVA- If you have not explored the management team and BOD you are missing out. If your into that kinda stuff. http://dova.com/about-us/leadership/
Usually after days on the bottom bolli and the RSI buried in oversold and volume... turns out to be a pretty good place to buy.
Volume alert
DOVA CFO -
Smart! It will all work out even with half.
Or just trying to be disciplined? Happy for you. I have too many on my watch list and lose track.
Hi gtm! Yes a boatload:)))
Nice pop!
EBIO sold, awesome swing. Saved a few, catalysts 5/21 and 6/21.